Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial

Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits in randomised controlled trials (RCT). However, the controlled nature of RCTs and the selected trial populations limit their generalizability to real-world practice. Substantial methodolo...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Cardiovascular Diabetology
المؤلفون الرئيسيون:	Puriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Bochra Zareini, Ulrik Pedersen-Bjergaard, Johan Sebastian Ohlendorff, Anders Munch, Mikkel Porsborg Andersen, Rasmus Bo Hasselbalch, Henrik Imberg, Viktor Tasseleus, Marcus Lind, Jonathan Valabhji, Pratik Choudhary, Kamlesh Khunti, Stefanie Schmid, Stefanie Lanzinger, Julia Mader, Thomas Alexander Gerds, Christian Torp-Pedersen, The REDDIE consortium
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2025-09-01
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12933-025-02924-0